Quantcast

Latest Anticoagulants Stories

2014-06-10 12:29:47

Additional Novel Oral Anticoagulants are Expected to Gain Approval in China for AF and VTE in the Next Three to Four Years, According to Findings from Decision Resources Group BURLINGTON, Mass., June 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs) in the Chinese market. Warfarin, the mainstay of anticoagulation treatment, is listed in the national essential drugs list and is...

2014-05-14 23:14:48

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. Chicago, IL (PRWEB) May 14, 2014 The drug safety advocates at DrugNews.net are alerting patients who have taken the anticoagulant Xarelto of new information on the site. A new report warns that the number of internal bleeding cases linked to the drug is steadily rising*. DrugNews is a free resource providing the latest product recalls, safety...

2014-04-28 16:29:07

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Antithrombotic Drugs: World Market 2013-2023 http://www.reportbuyer.com/pharma_healthcare/therapeutic/antithrombotic_drugs_world_market.html Report DetailsAntithrombotic agents - discover technological and commercial prospectsWhat does the future hold for treating conditions associated with thrombosis? Visiongain's updated report gives you forecasted revenues to 2023, explaining R&D...

2014-04-17 12:27:18

Surveyed MCOs Indicate That Tier Position of Pradaxa and Eliquis Unlikely to Change Even With Addition of VTE Treatment to Label, According to Findings from Decision Resources Group BURLINGTON, Mass., April 17, 2014 /PRNewswire/ -- Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use...

2014-04-02 08:32:43

MUNICH, Germany, April 2, 2014 /PRNewswire/ -- For European Media Only, Not for UK Media Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a five-fold increased risk of stroke compared with the general population[2] Daiichi Sankyo today announced its commitment to extend the PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). The extension of the registry will include a specific...

2014-03-31 08:29:45

RARITAN, N.J., March 31, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO(®) (rivaroxaban), the most studied and broadly indicated oral Factor Xa inhibitor in the world today. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient...

2014-03-31 08:28:47

First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion PARSIPPANY, N.J., March 31, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor...

2014-03-24 08:27:40

- Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials(1,2,3,4) TOKYO, March 24, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) enrolled in two phase...

2014-03-24 08:26:49

Results Show Highest Rate of Control Ever Observed with Warfarin in Real-world Setting, Surpassing Thresholds for Cost-Effectiveness of Newer Agents Identified in Five Recent Independent Studies WALTHAM, Mass., March 24, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR) today announced the publication of the largest-ever study of warfarin patient self-testing, which demonstrated that weekly International Normalized Ratio (INR) testing significantly improves control of warfarin, as measured...

2014-02-13 08:30:31

REG2 Extends Regado's Next-Generation Anticoagulation Therapy Franchise as Phase 3 REGULATE-PCI Clinical Trial of REG1 Advances BASKING RIDGE, N.J., Feb. 13, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration (FDA) has accepted the company's...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.